SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS, Inc. completed the acquisition of PXL-770 (now SCY-770), a novel AMPK activator targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). This oral therapy has shown promising safety and efficacy in prior trials and is expected to enter Phase 2 proof-of-concept trials in Q4 2026 with early readouts in 2027. The acquisition strengthe…